When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRK - Seattle Genetics' PADCEV nabs accelerated review for first-line bladder cancer
Merck & Company Inc.
Seattle Genetics (NASDAQ:SGEN) and collaboration partner Astellas Pharma (OTCPK:ALPMF) announce Breakthrough Therapy status in the U.S. for antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv), combined with Merck's (NYSE:MRK) Keytruda (pembrolizumab), for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in a first-line setting.
More news on: Seattle Genetics, Inc., Astellas Pharma Inc., Merck & Co., Inc., Healthcare stocks news, Stocks on the move,